UNSPSC 51412603: Dioxyline

This classification denotes a vasodilating agent with the molecular formula C22H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRE0P19C3Z, chemically known as 6,7-dimethoxy-1-(4-ethoxy-3-methoxybenzyl)-3-methylisoquinoline but generally known as dioxyline, which bears US NIH Compound Identifier 23140. SMILES: CCOC1=C(C=C(C=C1)CC2=[NH+]C(=CC3=CC(=C(C=C32)OC)OC)C)OC.OP(=O)(O)[O-].

UNSPSC 51412603 Dioxyline is a Commodity code covering pharmaceutical products supplied to state and local health agencies, fire rescue departments, and pharmacy benefit programs. State and local governments acquire dioxyline and related advanced life support medications through competitive sealed-bid and cooperative purchasing vehicles to stock emergency medical services, pharmacy programs, and institutional healthcare operations. The issuing bodies span municipal fire rescue services, state health commissions, and multistate cooperative purchasing alliances that coordinate procurement across participating jurisdictions and member agencies.

Recent solicitation activity shows a geographic concentration in Florida and Texas with multistate cooperative purchasing extending across the Upper Midwest and Pacific Northwest. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188) due April 8, 2026, seeking 1,020 units of diltiazem, 370 units of labetalol, and related injectable medications for Tampa Fire Rescue with a one-year contract term and $40,000 estimated value; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and wholesaler channels, signaling exploratory procurement strategy development. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) to participating state and local facilities across Minnesota and Oregon, with contract effectiveness July 1, 2026; scoring weighted price competitiveness at 75 percent and required compliance with cGMP, DSCSA, and FDA shelf-life standards.